4//SEC Filing
Vizirgianakis Stavros G. 4
Accession 0000899243-21-042368
CIK 0001665988other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:17 PM ET
Size
22.8 KB
Accession
0000899243-21-042368
Insider Transaction Report
Form 4
Vizirgianakis Stavros G.
Director
Transactions
- Award
Stock Option (Right to Buy)
2021-10-29+34,905→ 34,905 totalExercise: $12.27Exp: 2029-11-22→ Class A Common Stock (34,905 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+26,179→ 26,179 totalExercise: $7.57Exp: 2025-02-03→ Class A Common Stock (26,179 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+347,323→ 347,323 totalExercise: $5.63Exp: 2030-05-13→ Class A Common Stock (347,323 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+261,794→ 261,794 totalExercise: $12.71Exp: 2030-06-29→ Class A Common Stock (261,794 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+6,544→ 6,544 totalExercise: $3.33Exp: 2023-12-03→ Class A Common Stock (6,544 underlying) - Award
Restricted Stock Units
2021-10-29+2,895→ 2,895 total→ Class A Common Stock (2,895 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+19,634→ 19,634 totalExercise: $4.13Exp: 2026-02-04→ Class A Common Stock (19,634 underlying) - Award
Stock Option (Right to Buy)
2021-10-29+89,001→ 89,001 totalExercise: $7.78Exp: 2030-06-29→ Class A Common Stock (89,001 underlying)
Footnotes (5)
- [F1]This option is fully vested and exercisable.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);
- [F3](continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.
- [F4]Each restricted stock unit represents a contingent right to receive one share of Class A common stock
- [F5]The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in each case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
Documents
Issuer
Bioventus Inc.
CIK 0001665988
Entity typeother
Related Parties
1- filerCIK 0001559834
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:17 PM ET
- Size
- 22.8 KB